On October 28, 2025, Texas Attorney General Ken Paxton launched a high-stakes legal battle against Johnson & Johnson and its spinoff Kenvue, accusing them of misleading millions of pregnant women about the safety of Tylenol. The lawsuit, filed in Panola County, claims the companies concealed evidence linking prenatal acetaminophen use to autism and ADHD, potentially exposing them to tens of billions of dollars in damages. The case has ignited national debate, rattled investors, and placed the world’s most popular pain reliever under unprecedented scrutiny.
Mounting Concerns Over Tylenol’s Pregnancy Risks
Tylenol, known generically as acetaminophen, has long been considered the safest option for treating pain and fever during pregnancy. However, recent scientific studies and regulatory warnings have cast doubt on this reputation. In September 2025, the U.S. Food and Drug Administration (FDA) issued a public alert stating that prenatal acetaminophen use “may be associated” with increased risks of autism and ADHD in children. The Centers for Disease Control and Prevention (CDC) reports that about 1 in 31 U.S. children is diagnosed with autism, a statistic that weighs heavily on families and policymakers.
Despite these warnings, leading medical organizations urge caution in interpreting the data. The American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics maintain that no proven causal link exists between acetaminophen and autism. Dr. Steven J. Fleischman, president of ACOG, stated: “Suggestions that acetaminophen use in pregnancy causes autism are not only highly concerning to clinicians but also irresponsible when considering the harmful and confusing message they send to pregnant patients, including those who may need to rely on this beneficial medicine during pregnancy.”
Legal and Political Firestorm
Texas’s lawsuit marks the first time a state has taken such action against Tylenol’s manufacturers. The complaint alleges that Johnson & Johnson and Kenvue spent decades marketing Tylenol as safe for expectant mothers while downplaying or ignoring emerging evidence of neurological risks. Paxton, at a press conference, declared, “Big Pharma betrayed America. By holding them accountable, we will help make America healthy again.”
The case has quickly become a political flashpoint. Civil rights and autism advocacy groups have rallied behind the lawsuit, sharing personal stories and demanding answers. At the same time, critics—including U.S. Senator Bill Cassidy, a physician—dismiss the scientific basis for the claims. “As a doctor, the best evidence is there’s no relationship,” Cassidy told reporters. The debate has spilled into state legislatures, with some Texas lawmakers considering restrictions or bans on acetaminophen use during pregnancy.
National and Global Repercussions
The Texas lawsuit has sent shockwaves through the pharmaceutical industry and beyond. Johnson & Johnson’s stock dropped nearly 2% on the news, while Kenvue’s shares fell almost 4%. Market analysts warn that if Texas prevails, similar lawsuits could follow in other states, potentially costing the companies billions and forcing nationwide changes to drug labeling and marketing.
Other state attorneys general are closely monitoring the case, with some pledging to review their own consumer protection laws if Texas succeeds. Meanwhile, the FDA has begun the process of updating acetaminophen’s warning labels, and federal lawsuits from parents alleging Tylenol caused autism have been consolidated in a multidistrict litigation. Most of those claims were dismissed in 2024 due to insufficient scientific evidence, but appeals are ongoing.
Globally, health authorities urge restraint. The International Federation of Gynecology and Obstetrics (FIGO) recently stated that acetaminophen “remains the safest analgesic option for pregnant women when used appropriately.” Large European studies, including sibling comparisons, have found no link between prenatal acetaminophen use and autism. FIGO advises clinicians to reassure patients and continue recommending Tylenol judiciously, noting that alternatives like ibuprofen are known to be unsafe during pregnancy.
Personal Stakes for Texas Families
For many Texas families, the lawsuit is more than a legal battle—it’s a search for answers. Autism diagnoses have risen sharply in the state, mirroring national trends, and families affected by autism spectrum disorder continue to seek clarity about potential environmental and pharmaceutical factors.
The legal fight is being led by attorney Ashley Keller, who has been involved in opioid litigation. As the case moves forward, both sides are preparing for a lengthy courtroom showdown. Johnson & Johnson and Kenvue have vowed to “vigorously defend” themselves, insisting that the Texas claims “lack legal merit and scientific support.”
Looking Ahead: Science, Policy, and Public Trust
The outcome of Texas’s lawsuit could reshape drug safety standards and consumer protections nationwide. If the state prevails, it may trigger a wave of similar actions and stricter regulations on over-the-counter medications. If the case fails, courts may set a high bar for future claims linking common drugs to developmental disorders.
As the FDA continues its safety review and new studies emerge, the debate over Tylenol’s risks is likely to intensify. For now, families, doctors, and regulators are left navigating uncertainty—waiting for clearer answers from both the courtroom and the laboratory.